Daiken Medical Yönetim

Yönetim kriter kontrolleri 1/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Keiichi Yamada

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	20.7yrs
CEO sahipliği	19.0%
Yönetim ortalama görev süresi	Veri yok
Yönetim Kurulu ortalama görev süresi	4.4yrs

Son yönetim güncellemeleri

Recent updates

CEO

Keiichi Yamada (66 yo)

20.7yrs

Görev süresi

Mr. Keiichi Yamada has been the President at Daiken Medical Co., Ltd. since March 2004 and has been its Chief Executive Officer since January 2019. He served as General Manager of Technology Division of Da...

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Keiichi Yamada	President	20.7yrs	Veri yok	19.01% ¥ 2.8b
Masayuki Yamada	Executive VP of Corporate Planning & Director	42.3yrs	Veri yok	Veri yok
Hiroshi Daikuya	Independent Outside Director	8.4yrs	Veri yok	0.017% ¥ 2.6m
Kenji Mamasaki	Full Time Auditor	3.4yrs	Veri yok	0.031% ¥ 4.6m
Yoshimi Inagaki	Independent Outside Director	3.4yrs	Veri yok	Veri yok
Yuki Onishi	Auditor	4.4yrs	Veri yok	Veri yok
Hajime Murakami	Auditor	4.4yrs	Veri yok	Veri yok

4.4yrs

Ortalama Görev Süresi

63yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 7775 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.4 yıldır).

Daiken Medical Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

Insufficient new directors

Daiken Medical Co., Ltd., Annual General Meeting, Jun 20, 2024

Daiken Medical Co., Ltd., Annual General Meeting, Jun 21, 2023

Less than half of directors are independent

Daiken Medical Co., Ltd., Annual General Meeting, Jun 21, 2022

Less than half of directors are independent

Recent updates

Second quarter 2025 earnings released: EPS: JP¥11.10 (vs JP¥10.20 in 2Q 2024)

New minor risk - Market cap size

Upcoming dividend of JP¥9.00 per share

Daiken Medical Co., Ltd. to Report Q2, 2025 Results on Oct 31, 2024

First quarter 2025 earnings released: EPS: JP¥10.06 (vs JP¥8.49 in 1Q 2024)

Final dividend of JP¥9.00 announced

Insufficient new directors

Daiken Medical Co., Ltd. to Report Q1, 2025 Results on Jul 31, 2024

Full year 2024 earnings released: EPS: JP¥34.39 (vs JP¥24.78 in FY 2023)

Full year 2024 earnings released: EPS: JP¥34.39 (vs JP¥24.78 in FY 2023)

Daiken Medical Co., Ltd., Annual General Meeting, Jun 20, 2024

Daiken Medical Co., Ltd. to Report Fiscal Year 2024 Results on May 15, 2024

Upcoming dividend of JP¥12.00 per share

Third quarter 2024 earnings released: EPS: JP¥12.22 (vs JP¥9.02 in 3Q 2023)

New minor risk - Market cap size

Daiken Medical Co., Ltd. Announces Dividend for the Second Quarter-End of the Fiscal Year Ending March 31, 2024, Payable on December 1, 2023; Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024

Second quarter 2024 earnings released: EPS: JP¥10.20 (vs JP¥7.90 in 2Q 2023)

New minor risk - Market cap size

Upcoming dividend of JP¥9.00 per share at 4.0% yield

First quarter 2024 earnings released: EPS: JP¥8.49 (vs JP¥7.03 in 1Q 2023)

Daiken Medical Co., Ltd. Provides Dividend Guidance for the Second Quarter End and Full Year of 2024

Now 21% undervalued

Full year 2023 earnings released: EPS: JP¥24.78 (vs JP¥28.93 in FY 2022)

Daiken Medical Co., Ltd. to Report Q1, 2024 Results on Jul 31, 2023

Daiken Medical Co., Ltd. Provides Non-Consolidated Earnings Guidance for the Six Months Ending September 30, 2023 and Full Year March 31, 2024

Full year 2023 earnings released: EPS: JP¥24.78 (vs JP¥28.93 in FY 2022)

Daiken Medical Co., Ltd., Annual General Meeting, Jun 21, 2023

Upcoming dividend of JP¥11.00 per share at 3.7% yield

Daiken Medical Co., Ltd. Provides Fiscal Year End Dividend Guidance for the Year Ending March 31, 2023

Third quarter 2023 earnings released: EPS: JP¥9.02 (vs JP¥9.12 in 3Q 2022)

Daiken Medical Co., Ltd. to Report Q3, 2023 Results on Jan 31, 2023

Less than half of directors are independent

Second quarter 2023 earnings released: EPS: JP¥7.90 (vs JP¥7.80 in 2Q 2022)

Daiken Medical Co., Ltd. Provides Non-Consolidated Earnings Guidance for the Year Ending March 31, 2023

Daiken Medical Co., Ltd. to Report Q2, 2023 Results on Oct 31, 2022

Upcoming dividend of JP¥9.00 per share

Daiken Medical Co., Ltd. Provides Dividend Guidance for the Second Quarter Ending September 30, 2022 and the Full Year Ending March 31, 2023

First quarter 2023 earnings released: EPS: JP¥7.03 (vs JP¥6.13 in 1Q 2022)

Daiken Medical Co., Ltd. to Report Q1, 2023 Results on Jul 29, 2022

Full year 2022 earnings released: EPS: JP¥28.93 (vs JP¥23.50 in FY 2021)

Full year 2022 earnings released: EPS: JP¥28.93 (vs JP¥23.50 in FY 2021)

Daiken Medical Co., Ltd., Annual General Meeting, Jun 21, 2022

Price target decreased to JP¥600

Less than half of directors are independent

Daiken Medical Co., Ltd. to Report Fiscal Year 2022 Results on May 13, 2022

Upcoming dividend of JP¥11.00 per share

Daiken Medical Co., Ltd. Provides Non-Consolidated Earnings Guidance for the Year Ending March 31, 2022

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Second quarter 2022 earnings released: EPS JP¥7.80 (vs JP¥7.45 in 2Q 2021)

Upcoming dividend of JP¥9.00 per share

Daiken Medical Co., Ltd. Announces Non-Consolidated Earnings Guidance for the Six Months Ending September 30, 2021 and Full Year Ending March 31, 2022

Full year 2021 earnings released: EPS JP¥23.50 (vs JP¥29.90 in FY 2020)

Price target decreased to JP¥700

Daiken Medical Co., Ltd. Announces Non-Consolidated Earnings Guidance for the Six Months Ending September 30, 2021 and Full Year Ending March 31, 2022

Full year 2021 earnings released: EPS JP¥23.50 (vs JP¥29.90 in FY 2020)

Upcoming dividend of JP¥11.00 per share

New 90-day high: JP¥585

Third quarter 2021 earnings released: EPS JP¥9.82 (vs JP¥9.75 in 3Q 2020)

New 90-day high: JP¥579

New 90-day high: JP¥558

Daiken Medical Co., Ltd. to Report Q3, 2021 Results on Jan 29, 2021

Daiken Medical Co., Ltd. to Report Q2, 2021 Results on Oct 30, 2020

CEO

Görev süresi

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş